Connect with us

Stock Market Breaking News

Liberty Defense (SCAN.V) Signs MOU with the Utah Attorney General for Testing of HEXWAVE

Jon Phillip

Published

on

SALT LAKE CITY and VANCOUVER , May 22, 2019 /CNW/ – Liberty Defense Holdings Ltd. (“Liberty“) (TSXV: SCAN; FRANKFURT : LD2), a leader in security and weapons detection solutions, is announcing that it has signed a memorandum of understanding (MOU) with the Office of the Utah Attorney General to beta test HEXWAVE in the state.

The Utah Attorney General, Sean Reyes , is an elected constitutional officer in the executive branch of the state government of Utah . The attorney general is the chief legal officer and legal adviser in the state.

Special Report: This New Technology Could Transform A Multi-Billion-Dollar Industry!

“HEXWAVE can be applied in a variety of settings to provide a means to identify possible threats before they advance into attacks. We are excited that the Attorney General of Utah recognizes the potential value of this technology and the opportunity it provides for enhanced security in the state,” said Bill Riker , CEO of Liberty Defense.

The proposed testing with and through the Office of the Attorney General may include, but is not be limited to:

  • Sporting and concert arenas, stadiums and Olympic venues
  • Primary, secondary and higher education facilities
  • Places of worship, facilities and property owned by or affiliated with faith entities
  • Government offices, buildings and facilities
  • Amusement parks
  • Entertainment events, conventions, shows and festivals

The Attorney General has committed to work in Partnership with Liberty to facilitate introductions and advise interested parties and venues on the potential for HEXWAVE technology. The goal of this initiative is to improve public safety for the citizens of Utah .

“We are pleased to be a part of this phase of testing this new product. Innovation in this space is essential as the type and frequency of threats also evolve. We look forward to evaluating the capabilities of the HEXWAVE product,” said Attorney General Sean Reyes .

This beta testing phase is a key part of the product development process for HEXWAVE. The incremental testing of the system in actual facilities can help to ensure that it is aligned to market requirements. Beta testing is expected to begin later in 2019 and progress into 2020.

About Liberty Defense
Liberty provides security solutions for weapons detection in high volume foot traffic areas and has secured an exclusive licence from MIT Lincoln Laboratory, as well as a technology transfer agreement, for patents related to active 3D imaging technology that are packaged into the HEXWAVE product. The system is designed to provide discrete, modular and scalable protection to provide layered, stand-off detection capability. This is intended to provide a means to proactively counter evolving urban threats. The sensors with active 3D imaging and AI-enhanced automatic detection are designed to detect metallic and non-metallic firearms, knives, explosives and other threats. Liberty is committed to protecting communities and preserving peace of mind through superior security detection solutions. Learn more: LibertyDefense.com 

About Utah Attorney General
Since the admission of Utah as a state on January 4, 1896 the Attorney General has been an independently elected constitutional officer of the executive department and serves four-year terms. The current Utah Attorney General is Sean Reyes .

About Utah 
Utah is a state in the western United States . It became the 45th state admitted to the U.S. on January 4, 1896 . Utah is the 13th-largest by area, 31st-most-populous, and 10th-least-densely populated of the 50 United States. Utah was the home of the 2002 Olympic Winter Games and may yet host future Olympic games.

FORWARD-LOOKING STATEMENTS

When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. Although Liberty believes, in light of the experience of their respective officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in the forward-looking statements and information in this press release are reasonable, undue reliance should not be placed on them because the parties can give no assurance that such statements will prove to be correct. The forward-looking statements and information in this press release include, amongst others, information relating to the expectation of future MOUs and validation of technology. Such statements and information reflect the current view of Liberty. There are risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: (a) there is no assurance that Liberty will obtain further MOUs. These fluctuations may adversely affect the price of the Liberty’s securities, regardless of its operating performance. There are a number of important factors that could cause Liberty’s actual results to differ materially from those indicated or implied by forward-looking statements and information. Such factors include, among others: currency fluctuations; limited business history of the parties; disruptions or changes in the credit or security markets; results of operation activities and development of projects; project cost overruns or unanticipated costs and expenses; and general market and industry conditions. The parties undertake no obligation to comment on analyses, expectations or statements made by third parties in respect of their securities or their respective financial or operating results (as applicable).

Liberty cautions that the foregoing list of material factors is not exhaustive. When relying on the party’s forward-looking statement and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The party has assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. The forward-looking information contained in this press release represents the expectations of the party as of the date of this press release and, accordingly, are subject to change after such date. The party does not undertake to update this information at any particular time except as required in accordance with applicable laws.

All amounts referred to herein are in Canadian dollars unless otherwise indicated.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 04/15/2018 – 5/15/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter now extended through June 21, 2019. We were paid $350,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE

Continue Reading
Click to comment

Featured

ParcelPal (PTNYF) (PKG) Announces Delivery Agreement with Aphria Inc. (APHA)

Joe Samuel

Published

on

defense industry merger

VANCOUVER, British Columbia , Aug. 22, 2019 /CNW/ — ParcelPal Technology Inc. (“ParcelPal” or the “Company”), (PKG.CN) (PT0.F) (PTNYF) is pleased to announce that it secured a distribution agreement with one of the largest Canadian Federally Licensed producers in Canada , Aphria Inc. (“Aphria”) (APHA.TO) (APHA) for delivery of medical cannabis to patients.

This initiative between ParcelPal and Aphria will commence with Calgary as the catalyst city. Patients can purchase product from Aphria’s online store and utilize the ParcelPal technology platform to receive their product safely and legally. All customers will be able to track their purchase in real time and have their product delivered directly to any location they specify within Calgary .

In collaboration with ParcelPal, and MADD Canada are confident that this program will not only enable consumers unfettered access to their medicinal cannabis in a safe and timely manner but will furthermore assist in eliminating impaired drivers from our roadways by removing their need to drive to or from cannabis stores for product.

ParcelPal expects that additional cities will be rapidly added to its distribution network across Canada . As time and regulations allow, ParcelPal’s cannabis network will continue to grow, with the goal of capturing a major piece of Canada’s $4.0B legal cannabis market.

President and CEO, Kelly Abbott states, “The legal cannabis space continues to serve as a sector filled with significant growth potential for ParcelPal. Management believes that we are launching our legal cannabis delivery platform at the ideal time as legislation across the country continues to expand the addressable cannabis marketplace and we are thrilled to be working with Aphria on this exciting new venture that will help to kick off the next evolution of our company. We expect to leverage numerous business opportunities in the upcoming year. We look forward to establishing ourselves as a market leader in the cannabis delivery space and capturing meaningful market share in 2019 and beyond.”

About ParcelPal Technology Inc.

ParcelPal is a technology-driven logistics company that connects consumers to the goods they love. Customers can shop at partner businesses and through the ParcelPal technology receive their purchased goods within an hour. The Company offers on-demand delivery of merchandise from leading retailers, restaurants, marijuana dispensaries and liquor stores in Vancouver and soon in major cities Canada -wide.

ParcelPal Website: www.parcelpal.com

The Canadian Securities Exchange (“CSE”) or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release that has been prepared by management.

CSE – Symbol: PKG
FSE – Symbol: PT0
OTC – Symbol: PTNYF

Forward Looking Information.

We seek safe harbour.

This news release contains forward looking statements relating to the Proposed Transaction, and the future potential of ParcelPal. Forward looking statements are often identified by terms such as “will”, “may”, “should”, “intends”, “anticipates”, “expects”, “plans” and similar expressions. All statements other than statements of historical fact, included in this release are forward looking statements that involve risks and uncertainties. These risks and uncertainties include, without limitation, the risk that the Proposed Transaction will not be completed due to, among other things, failure to execute definitive documentation, failure to complete satisfactory due diligence, failure to receive the approval of the CSE and the risk that ParcelPal will not be successful due to, among other things, general risks relating to the mobile application industry, failure of ParcelPal to gain market acceptance and potential challenges to the intellectual property utilized in ParcelPal. There can be no assurance that any forward looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

The Company cannot guarantee that any forward looking statement will materialize and the reader is cautioned not to place undue reliance on any forward looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward looking statements contained in this news release are expressly qualified by this cautionary statement. The forward looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward looking statements as expressly required by Canadian securities laws.

Contact:
Peter Hinam
Investor Relations
peter@parcelpal.com
+1-604-401-8700

View original content on PRNewswire.com: http://www.prnewswire.com/news-releases/parcelpal-announces-delivery-agreement-with-aphria-inc-300905818.html

MIDAM VENTURES LLC has been compensated $75,000 per month by a ParcelPal Technology, Inc. for a period beginning September 1, 2018 and ending February 1, 2019 to publicly disseminate information about (PTNYF/PKG) to publicly disseminate information about (PTNYF/PKG). Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to April 1, 2019. Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to May 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to June 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to July 1, 2019. We may buy or sell additional shares of (PTNYF/PKG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares. Read Full Disclaimer Here

Continue Reading

Biotechnology

PharmaCyte Biotech to Hold Special Shareholder Meeting

A. Lawrence

Published

on

biotechnology stock price

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–

PharmaCyte Biotech, Inc. (PMCB), a clinical-stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will hold a Special Shareholder Meeting on September 11, 2019. The shareholder meeting, not to be confused with a shareholder conference call, will be held at the Courtyard by Marriott in Irvine, California, and will begin at 11:00 a.m. Pacific Daylight Time.

During the meeting there will be an update on PharmaCyte’s current research-related projects followed by a question and answer session regarding the update. The meeting will then turn to management matters, such as: (i) amending PharmaCyte’s Articles of Incorporation to provide the Board of Directors (“Board”) the power to designate the rights and preferences of PharmaCyte’s preferred stock; (ii) election of six directors as nominated by the Board’s Nominating Committee and approved by the Board, each to serve a one-year term; (iii) ratification of the appointment of Armanino LLP as PharmaCyte’s independent registered public accounting firm for the fiscal year ending April 30, 2020 and (iv) to consider and act upon any other business as may properly come before the Special Shareholder Meeting.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “This shareholder meeting will be the first during my tenure as CEO. Since the new management team took over in 2014, we have faced untold challenges and hurdles virtually every day. We have persevered. We believe we’re on the brink of a new dawn for the company as we work collaboratively with so many stellar professional colleagues to showcase the unique Cell-in-a-Box® technology in which so many have worked so diligently over the past several years. We feel that it is important to realize our full potential while, at the same time, bringing value to and protecting our shareholders who have stood by us for so long.

“We look forward to meeting many of our long-standing and new shareholders who can attend and in implementing the steps that will enable us to succeed on numerous fronts.”

About PharmaCyte Biotech:

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190821005275/en/

Contact:
Dr. Gerald W. Crabtree
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Featured

Stock Price Wednesday Morning Update – August 21, 2019

Joe Samuel

Published

on

biotech stocks to watch

PharmaCyte Biotech to Hold Special Shareholder Meeting

PharmaCyte Biotech, Inc. (PMCB), a clinical-stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will hold a Special Shareholder Meeting on September 11, 2019.

See More On This – CLICK HERE


Must Read Biotech Stock Report

With a wave of groundbreaking products in the pipeline, biotechnology could be poised to keep churning higher for the foreseeable future. But how can you get in on the ground floor of the next big wave in biotech?

Continue Reading


2 Food Delivery Stocks To Watch Before The End Of Summer

The food delivery industry in the United States has grown into a behemoth and although the margins are extremely thin, investors are willing to bet billions on some of the biggest food delivery companies. At this point in time, companies are fighting among themselves to gain supremacy in this space and competition is heating up as they look to grab market share from each other.

Read More Here


2 Chinese Stocks Making Bullish Moves

The trade war with the United States and an economic slowdown for the first time in three decades has cratered the markets in China. China-based stocks have generally underperformed over the course of the past year. But even during such a slowdown, some stock prices have been showing bullish tendencies. Here is a look at two such China-based companies that have seen stock prices climb.

See For Yourself

biotech stock to buy 2019

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com